XML 45 R5.htm IDEA: XBRL DOCUMENT  v2.3.0.11
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands
6 Months Ended
Jun. 30, 2011
Jun. 30, 2010
CASH FLOWS FROM OPERATING ACTIVITIES:    
Consolidated net income $ 63,982 $ 47,850
Adjustments to reconcile net income to net cash provided by operating activities:    
Deferred tax (benefit) expense (800) 2,946
Depreciation and amortization 8,145 6,735
Amortization of programming rights 146,211 107,789
Amortization of sublicensing rights and own production cost 825 2,580
Stock based compensation expense 14,836 15,803
Equity in income of unconsolidated investees (367) (213)
Foreign currency gains (1,747) (883)
Changes in operating assets and liabilities:    
Trade accounts receivable 14,284 (2,364)
Prepayments (7,142) (2,015)
Other assets 2,611 (4,524)
Accounts payable and accrued liabilities (1,133) 5,740
Deferred revenue (7,530) 4,363
Other liabilities (16,585) (11,439)
Dividends received from equity investees 271  
Acquisition of programming and sublicensing rights (177,304) (121,650)
Net cash provided by operating activities 38,557 50,718
CASH FLOWS FROM INVESTING ACTIVITIES:    
Acquisitions of property and equipment and intangible assets (12,445) (5,333)
Acquisitions of businesses, net of cash acquired (20,935) (12,955)
Proceeds from sale of businesses, net of cash disposed   2,026
Increase in restricted cash (3,377)  
Receipts from/(investments in) deposits 27,130 (64,997)
Net cash used in investing activities (9,627) (81,259)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from exercise of stock options 5,159 24,781
Repayments of loans   (28,250)
Decrease in restricted cash   131
Dividends paid to stockholders (59,714) (20,156)
Dividends paid to noncontrolling interest (3,464) (2,120)
Net cash used in financing activities (58,019) (25,614)
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS 4,045 594
Net decrease in cash and cash equivalents (25,044) (55,561)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 59,565 84,441
CASH AND CASH EQUIVALENTS AT END OF PERIOD $ 34,521 $ 28,880